Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

Basit Öğe Kaydı
dc.authoridOzturk, Banu/0000-0003-0290-8787
dc.authoridharputluoglu, hakan/0000-0001-8537-5941
dc.authoridbenekli, mustafa/0000-0003-3184-4946
dc.authoridÖksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646
dc.authoridUlas, Arife/0000-0003-2918-2592
dc.authoridSevinç, Alper/0000-0002-0499-8918
dc.authoridKaplan, Muhammet Ali/0000-0003-0882-0524
dc.authorwosidOzturk, Banu/AAD-4358-2019
dc.authorwosidSevinc, Alper/KFQ-6440-2024
dc.authorwosidharputluoglu, hakan/ABI-6451-2020
dc.authorwosidBerk, Veli/IXE-0017-2023
dc.authorwosidbenekli, mustafa/AAE-4555-2020
dc.authorwosidÖksüzoğlu Çakmak, Ömür Berna/HKN-6428-2023
dc.authorwosidUlas, Arife/HGD-4686-2022
dc.contributor.authorCetin, Bulent
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorKoral, Lokman
dc.contributor.authorUlas, Arife
dc.contributor.authorDane, Faysal
dc.contributor.authorTurker, Ibrahim
dc.date.accessioned2024-08-04T20:36:15Z
dc.date.available2024-08-04T20:36:15Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: We investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) treated with lapatinib and capecitabine (LC). Patients and Methods: A total of 203 patients with HER2+ MBC, who had progressed after trastuzumab-containing chemotherapy, were retrospectively evaluated in 11 centers between September 2009 and May 2011. 85 patients who had developed BMs before the initiation of treatment with LC were included. All patients had received prior cranial radiotherapy. All patients were treated with the combination of lapatinib (1,250 mg/day continuously) and capecitabine (2,000 mg/m(2) on days 1-14 of a 21-day cycle). Results: The median follow-up was 10.5 months (range 1-38 months). An overall response rate of 27.1% was achieved, including complete response in 2 (2.4%) and partial response in 21 (24.7%) patients. Median progression-free survival was 7 months (95% confidence interval (CI) 5-9), with a median overall survival of 13 months (95% Cl 9-17). The most common side effects were hand-foot syndrome (58.8%), nausea (55.3%), fatigue (48.9%), anorexia (45.9%), rash (36.5%), and diarrhea (35.4%). Grade 3-4 toxicities were hand-foot syndrome (9.4%), diarrhea (8.3%), fatigue (5.9%), and rash (4.7%). There were no symptomatic cardiac events. Conclusion: LC combination therapy was effective and well-tolerated in patients with HER2+ MBC with BMs, who had progressive disease after trastuzumab-containing therapy.en_US
dc.identifier.doi10.1159/000345040
dc.identifier.endpage745en_US
dc.identifier.issn0378-584X
dc.identifier.issn1423-0240
dc.identifier.issue12en_US
dc.identifier.pmid23207619en_US
dc.identifier.scopus2-s2.0-84871057384en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage740en_US
dc.identifier.urihttps://doi.org/10.1159/000345040
dc.identifier.urihttps://hdl.handle.net/11616/95885
dc.identifier.volume35en_US
dc.identifier.wosWOS:000312469400003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOnkologieen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHER2en_US
dc.subjectMetastatic breast canceren_US
dc.subjectLapatiniben_US
dc.subjectBrain metastasesen_US
dc.titleLapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu